Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SM17 Phase 1 in Healthy Subjects
NCT05332834Phase 1Completed
- Sponsor
- SinoMab BioScience Limited
- Start
- Jun 2022
- Primary completion
- Sep 2023
- Modality
- IgG Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in asthma comparing Drug SM17 with Drug Placebo (2 arms). Primary endpoint: Number of subjects with adverse events. Started Jun 2022; status: completed.
02
Drugs
SM17
03
Conditions
asthma
Beyond the preview
Go deeper on NCT05332834.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05332834.